{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:14:29Z","timestamp":1788545669853,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nutrimedhealth"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04546-8","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:02:06Z","timestamp":1788544926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of glioblastoma in the elderly"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-5073","authenticated-orcid":false,"given":"Idoia","family":"Morilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5183-2709","authenticated-orcid":false,"given":"Edinson","family":"Caviedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-0553","authenticated-orcid":false,"given":"Regina","family":"Giron\u00e9s Sarri\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-9278","authenticated-orcid":false,"given":"Borja","family":"L\u00f3pez de San Vicente Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8676-6292","authenticated-orcid":false,"given":"Natalia","family":"Luque Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6871","authenticated-orcid":false,"given":"Sonia","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-0988","authenticated-orcid":false,"given":"Juana M.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-9002","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Vaz-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"4546_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme-literature review. Cancers (Basel). 2022;14:2412. https:\/\/doi.org\/10.3390\/cancers14102412.","journal-title":"Cancers (Basel)"},{"key":"4546_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"4546_CR3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24:v1-95. https:\/\/doi.org\/10.1093\/neuonc\/noac202.","journal-title":"Neuro Oncol"},{"key":"4546_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.17","volume":"1","author":"M Weller","year":"2015","unstructured":"Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. https:\/\/doi.org\/10.1038\/nrdp.2015.17.","journal-title":"Nat Rev Dis Primers"},{"key":"4546_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa065901","volume":"356","author":"F Keime-Guibert","year":"2007","unstructured":"Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527\u201335. https:\/\/doi.org\/10.1056\/NEJMoa065901.","journal-title":"N Engl J Med"},{"key":"4546_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14:307\u201320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6.","journal-title":"Neurotherapeutics"},{"key":"4546_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765\u201373. https:\/\/doi.org\/10.1056\/NEJMoa0808710.","journal-title":"N Engl J Med"},{"key":"4546_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331.","journal-title":"N Engl J Med"},{"key":"4546_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462\u201377. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034.","journal-title":"Cell"},{"key":"4546_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"4546_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","volume":"118","author":"M Niyazi","year":"2016","unstructured":"Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline \u201ctarget delineation of glioblastomas.\u201d Radiother Oncol. 2016;118:35\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2015.12.003.","journal-title":"Radiother Oncol"},{"key":"4546_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","volume":"27","author":"Q-L Xue","year":"2011","unstructured":"Xue Q-L. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27:1\u201315. https:\/\/doi.org\/10.1016\/j.cger.2010.08.009.","journal-title":"Clin Geriatr Med"},{"key":"4546_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101509","volume":"11","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, Bergo E, Caccese M, Padovan M, Bellu L, Brunello A, et al. Validation of the comprehensive geriatric assessment as a predictor of mortality in elderly glioblastoma patients. Cancers (Basel). 2019;11:1509. https:\/\/doi.org\/10.3390\/cancers11101509.","journal-title":"Cancers (Basel)"},{"key":"4546_CR14","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/s1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315\u201329. https:\/\/doi.org\/10.1016\/s1470-2045(17)30194-8.","journal-title":"Lancet Oncol"},{"key":"4546_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(12)70164-X.","journal-title":"Lancet Oncol"},{"key":"4546_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030336","volume":"11","author":"G Minniti","year":"2019","unstructured":"Minniti G, Lombardi G, Paolini S. Glioblastoma in elderly patients: current management and future perspectives. Cancers (Basel). 2019;11:336. https:\/\/doi.org\/10.3390\/cancers11030336.","journal-title":"Cancers (Basel)"},{"key":"4546_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3171\/2022.8.JNS221068","volume":"138","author":"F Laigle-Donadey","year":"2023","unstructured":"Laigle-Donadey F, Metellus P, Guyotat J, Menei P, Proust F, Dufour H, et al. Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d\u2019Expression Fran\u00e7aise (ANOCEF) trial. J Neurosurg. 2023;138:1199\u2013205. https:\/\/doi.org\/10.3171\/2022.8.JNS221068.","journal-title":"J Neurosurg"},{"key":"4546_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11060-018-2964-8","volume":"140","author":"DH Heiland","year":"2018","unstructured":"Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, et al. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neurooncol. 2018;140:385\u201391. https:\/\/doi.org\/10.1007\/s11060-018-2964-8.","journal-title":"J Neurooncol"},{"key":"4546_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.900382","volume":"12","author":"J Klingenschmid","year":"2022","unstructured":"Klingenschmid J, Krigers A, Kerschbaumer J, Thom\u00e9 C, Pinggera D, Freyschlag CF. Surgical management of malignant glioma in the elderly. Front Oncol. 2022;12:900382. https:\/\/doi.org\/10.3389\/fonc.2022.900382.","journal-title":"Front Oncol"},{"key":"4546_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03478-6","volume":"22","author":"D L\u00f6fgren","year":"2022","unstructured":"L\u00f6fgren D, Valachis A, Olivecrona M. Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas - a retrospective population-based study. BMC Geriatr. 2022;22:805. https:\/\/doi.org\/10.1186\/s12877-022-03478-6.","journal-title":"BMC Geriatr"},{"key":"4546_CR21","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","volume":"22","author":"W Roa","year":"2004","unstructured":"Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583\u20138. https:\/\/doi.org\/10.1200\/JCO.2004.06.082.","journal-title":"J Clin Oncol"},{"key":"4546_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(12)70265-6.","journal-title":"Lancet Oncol"},{"key":"4546_CR23","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","volume":"33","author":"W Roa","year":"2015","unstructured":"Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33:4145\u201350. https:\/\/doi.org\/10.1200\/JCO.2015.62.6606.","journal-title":"J Clin Oncol"},{"key":"4546_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/nejmoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027\u201337. https:\/\/doi.org\/10.1056\/nejmoa1611977.","journal-title":"N Engl J Med"},{"key":"4546_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100761","volume":"46","author":"NK Mazarakis","year":"2024","unstructured":"Mazarakis NK, Robinson SD, Sinha P, Koutsarnakis C, Komaitis S, Stranjalis G, et al. Management of glioblastoma in elderly patients: a review of the literature. Clin Transl Radiat Oncol. 2024;46:100761. https:\/\/doi.org\/10.1016\/j.ctro.2024.100761.","journal-title":"Clin Transl Radiat Oncol"},{"key":"4546_CR26","doi-asserted-by":"publisher","first-page":"vdae211","DOI":"10.1093\/noajnl\/vdae211","volume":"6","author":"A Malmstr\u00f6m","year":"2024","unstructured":"Malmstr\u00f6m A, Oppong FB, Ocallaghan CJ, Wick W, Laperriere N, Gorlia T, et al. Prognostic factors for overall survival in elderly patients with glioblastoma: analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE6) trial. Neurooncol Adv. 2024;6:vdae211. https:\/\/doi.org\/10.1093\/noajnl\/vdae211.","journal-title":"Neurooncol Adv"},{"key":"4546_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11912-020-00951-6","volume":"22","author":"C L\u00fctgendorf-Caucig","year":"2020","unstructured":"L\u00fctgendorf-Caucig C, Freyschlag C, Masel EK, Marosi C. Guiding treatment choices for elderly patients with glioblastoma by a comprehensive geriatric assessment. Curr Oncol Rep. 2020;22:93. https:\/\/doi.org\/10.1007\/s11912-020-00951-6.","journal-title":"Curr Oncol Rep"},{"key":"4546_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.777120","volume":"12","author":"H Krenzlin","year":"2021","unstructured":"Krenzlin H, Jankovic D, Alberter C, Kalasauskas D, Westphalen C, Ringel F, et al. Frailty in glioblastoma is independent from chronological age. Front Neurol. 2021;12:777120. https:\/\/doi.org\/10.3389\/fneur.2021.777120.","journal-title":"Front Neurol"},{"key":"4546_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/curroncol29010032","volume":"29","author":"M Chahal","year":"2022","unstructured":"Chahal M, Thiessen B, Mariano C. Treatment of older adult patients with glioblastoma: moving towards the inclusion of a comprehensive geriatric assessment for guiding management. Curr Oncol. 2022;29:360\u201376. https:\/\/doi.org\/10.3390\/curroncol29010032.","journal-title":"Curr Oncol"},{"key":"4546_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cncr.11097","volume":"97","author":"AA Brandes","year":"2003","unstructured":"Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97:657\u201362. https:\/\/doi.org\/10.1002\/cncr.11097.","journal-title":"Cancer"},{"key":"4546_CR31","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1002\/cncr.24406","volume":"115","author":"AA Brandes","year":"2009","unstructured":"Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009;115:3512\u20138. https:\/\/doi.org\/10.1002\/cncr.24406.","journal-title":"Cancer"},{"key":"4546_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2011.06.1992","volume":"83","author":"G Minniti","year":"2012","unstructured":"Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012;83:93\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.06.1992.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4546_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013261.pub2","volume":"3","author":"C Hanna","year":"2020","unstructured":"Hanna C, Lawrie TA, Rogozi\u0144ska E, Kernohan A, Jefferies S, Bulbeck H, et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020;3:CD013261. https:\/\/doi.org\/10.1002\/14651858.CD013261.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4546_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1578406","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Ma L, Fu X, Zhang Y, Zheng J, Chen Z. Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database. Front Pharmacol. 2025;16:1578406. https:\/\/doi.org\/10.3389\/fphar.2025.1578406.","journal-title":"Front Pharmacol"},{"key":"4546_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1437436","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Jia P, Fang Y, Zhu W, Gong Y, Fan T, et al. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database. Front Pharmacol. 2024;15:1437436. https:\/\/doi.org\/10.3389\/fphar.2024.1437436.","journal-title":"Front Pharmacol"},{"key":"4546_CR36","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA. 2015;314:2535. https:\/\/doi.org\/10.1001\/jama.2015.16669.","journal-title":"JAMA"},{"key":"4546_CR37","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA. 2017;318:2306. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA"},{"key":"4546_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671972","volume":"11","author":"Z Ram","year":"2021","unstructured":"Ram Z, Kim C-Y, Hottinger AF, Idbaih A, Nicholas G, Zhu J-J. Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol. 2021;11:671972. https:\/\/doi.org\/10.3389\/fonc.2021.671972.","journal-title":"Front Oncol"},{"key":"4546_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/nop\/npab026","volume":"8","author":"O Regev","year":"2021","unstructured":"Regev O, Merkin V, Blumenthal DT, Melamed I, Kaisman-Elbaz T. Tumor-treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neurooncol Pract. 2021;8:426\u201340. https:\/\/doi.org\/10.1093\/nop\/npab026.","journal-title":"Neurooncol Pract"},{"key":"4546_CR40","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_552_2022","volume":"13","author":"HP Prajapati","year":"2022","unstructured":"Prajapati HP, Singh DK. Recurrent glioblastoma in elderly: options and decision for the treatment. Surg Neurol Int. 2022;13:397. https:\/\/doi.org\/10.25259\/SNI_552_2022.","journal-title":"Surg Neurol Int"},{"key":"4546_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11060-017-2573-y","volume":"135","author":"M Zanello","year":"2017","unstructured":"Zanello M, Roux A, Ursu R, Peeters S, Bauchet L, Noel G, et al. Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment? J Neurooncol. 2017;135:285\u201397. https:\/\/doi.org\/10.1007\/s11060-017-2573-y.","journal-title":"J Neurooncol"},{"key":"4546_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11060-015-1987-7","volume":"126","author":"J Socha","year":"2016","unstructured":"Socha J, Kepka L, Ghosh S, Roa W, Kumar N, Sinaika V, et al. Outcome of treatment of recurrent glioblastoma multiforme in elderly and\/or frail patients. J Neurooncol. 2016;126:493\u20138. https:\/\/doi.org\/10.1007\/s11060-015-1987-7.","journal-title":"J Neurooncol"},{"key":"4546_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11060-020-03393-z","volume":"146","author":"MT Fari\u00f1a Nu\u00f1ez","year":"2020","unstructured":"Fari\u00f1a Nu\u00f1ez MT, Franco P, Cipriani D, Neidert N, Behringer SP, Mader I, et al. Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit. J Neurooncol. 2020;146:381\u20137. https:\/\/doi.org\/10.1007\/s11060-020-03393-z.","journal-title":"J Neurooncol"},{"key":"4546_CR44","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.wneu.2018.01.211","volume":"113","author":"Y-R Chen","year":"2018","unstructured":"Chen Y-R, Sole J, Ugiliweneza B, Johnson E, Burton E, Woo SY, et al. National trends for reoperation in older patients with glioblastoma. World Neurosurg. 2018;113:e179\u201389. https:\/\/doi.org\/10.1016\/j.wneu.2018.01.211.","journal-title":"World Neurosurg"},{"key":"4546_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11060-019-03101-6","volume":"142","author":"C Straube","year":"2019","unstructured":"Straube C, Antoni S, Gempt J, Zimmer C, Meyer B, Schlegel J, et al. Re-irradiation in elderly patients with glioblastoma: a single institution experience. J Neurooncol. 2019;142:327\u201335. https:\/\/doi.org\/10.1007\/s11060-019-03101-6.","journal-title":"J Neurooncol"},{"key":"4546_CR46","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192\u2013202. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.011.","journal-title":"Eur J Cancer"},{"key":"4546_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.902929","author":"Z Ram","year":"2022","unstructured":"Ram Z, Kim C-Y, Hottinger AF, Idbaih A, Nicholas G, Zhu J-J. Corrigendum: efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.902929.","journal-title":"Front Oncol"},{"key":"4546_CR48","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/nejmoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954\u201363. https:\/\/doi.org\/10.1056\/nejmoa1707358.","journal-title":"N Engl J Med"},{"key":"4546_CR49","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2019-0004","volume":"8","author":"R Addeo","year":"2019","unstructured":"Addeo R, Lamberti G, Simonetti G, Iodice P, Marinelli A, Montella L, et al. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncol. 2019;8:CNS32\u2013CNS32. https:\/\/doi.org\/10.2217\/cns-2019-0004.","journal-title":"CNS Oncol"},{"key":"4546_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-013-1125-3","volume":"113","author":"M Santoni","year":"2013","unstructured":"Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, et al. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol. 2013;113:397\u2013401. https:\/\/doi.org\/10.1007\/s11060-013-1125-3.","journal-title":"J Neurooncol"},{"key":"4546_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/1078155220940396","volume":"27","author":"E Barrascout","year":"2021","unstructured":"Barrascout E, Lamuraglia M. Glioblastoma and bevacizumab in elderly patients: monocentric study. J Oncol Pharm Pract. 2021;27:842\u20136. https:\/\/doi.org\/10.1177\/1078155220940396.","journal-title":"J Oncol Pharm Pract"},{"key":"4546_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rud\u00e0 R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20:110\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(18)30675-2.","journal-title":"Lancet Oncol"},{"key":"4546_CR53","unstructured":"European Medicines Agency. Stivarga n.d."},{"key":"4546_CR54","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Stivarga. Ficha t\u00e9cnica n.d."},{"key":"4546_CR55","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","volume":"21","author":"M Weller","year":"2015","unstructured":"Weller M, Tabatabai G, K\u00e4stner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21:2057\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2737.","journal-title":"Clin Cancer Res"},{"key":"4546_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/mi.2025.245","volume":"5","author":"AM Al-Ghaithi","year":"2025","unstructured":"Al-Ghaithi AM, Al-Barkhati S, Al Abri AM, Al Husaini D, Al-Hajri A, Al-Saadi T. Palliative care in patients with glioblastoma: a systematic review. Med Int. 2025;5:46. https:\/\/doi.org\/10.3892\/mi.2025.245.","journal-title":"Med Int"},{"key":"4546_CR57","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","volume":"42","author":"JJ Sanders","year":"2024","unstructured":"Sanders JJ, Temin S, Ghoshal A, Alesi ER, Ali ZV, Chauhan C, et al. Palliative care for patients with cancer: ASCO guideline update. J Clin Oncol. 2024;42:2336\u201357. https:\/\/doi.org\/10.1200\/JCO.24.00542.","journal-title":"J Clin Oncol"},{"key":"4546_CR58","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Palliative care V.3.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed August 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"4546_CR59","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Older Adult Oncology V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed August 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"4546_CR60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.wneu.2024.09.125","volume":"192","author":"II Okon","year":"2024","unstructured":"Okon II, Osama M, Akpan A, Fabrini Paleare LF, Ferreira MY, Shafqat MD, et al. The evolving role of palliative care in older people with glioblastoma. World Neurosurg. 2024;192:140\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2024.09.125.","journal-title":"World Neurosurg"},{"key":"4546_CR61","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/0269216314526272","volume":"28","author":"A Brinkman-Stoppelenburg","year":"2014","unstructured":"Brinkman-Stoppelenburg A, Rietjens JAC, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014;28:1000\u201325. https:\/\/doi.org\/10.1177\/0269216314526272.","journal-title":"Palliat Med"},{"key":"4546_CR62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/nop\/npad070","volume":"11","author":"C Stadler","year":"2024","unstructured":"Stadler C, Gramatzki D, Le Rhun E, Hottinger AF, Hundsberger T, Roelcke U, et al. Glioblastoma in the oldest old: clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neuro-oncol Pract. 2024;11:132\u201341. https:\/\/doi.org\/10.1093\/nop\/npad070.","journal-title":"Neuro-oncol Pract"},{"key":"4546_CR63","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/CCO.0000000000000876","volume":"34","author":"PB van der Meer","year":"2022","unstructured":"van der Meer PB, Taphoorn MJB, Koekkoek JAF. Management of epilepsy in brain tumor patients. Curr Opin Oncol. 2022;34:685\u201390. https:\/\/doi.org\/10.1097\/CCO.0000000000000876.","journal-title":"Curr Opin Oncol"},{"key":"4546_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/CCO.0000000000001192","volume":"37","author":"T Kazda","year":"2025","unstructured":"Kazda T, Hnidakova L, Minniti G. Reirradiation in recurrent glioblastoma. Curr Opin Oncol. 2025;37:580\u20138. https:\/\/doi.org\/10.1097\/CCO.0000000000001192.","journal-title":"Curr Opin Oncol"},{"key":"4546_CR65","doi-asserted-by":"publisher","first-page":"e624","DOI":"10.1016\/j.wneu.2022.07.070","volume":"166","author":"MR Voisin","year":"2022","unstructured":"Voisin MR, Zuccato JA, Wang JZ, Zadeh G. Surgery for recurrent glioblastoma multiforme: a retrospective case control study. World Neurosurg. 2022;166:e624\u201331. https:\/\/doi.org\/10.1016\/j.wneu.2022.07.070.","journal-title":"World Neurosurg"},{"key":"4546_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J, et al. Use of bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer. 2023;23:544. https:\/\/doi.org\/10.1186\/s12885-023-11043-6.","journal-title":"BMC Cancer"},{"key":"4546_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.rxeng.2025.101621","volume":"67","author":"C Pineda Ibarra","year":"2025","unstructured":"Pineda Ibarra C, Oleaga Zufiria L, Valduvieco Ruiz I, Pineda Losada E, Pujol Farr\u00e9 T, Gonz\u00e1lez Ortiz S. RANO 2.0: update to the response assessment for gliomas. Radiolog\u00eda (English Edition). 2025;67:101621. https:\/\/doi.org\/10.1016\/j.rxeng.2025.101621.","journal-title":"Radiolog\u00eda (English Edition)"},{"key":"4546_CR68","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","volume":"18","author":"A Pace","year":"2017","unstructured":"Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rud\u00e0 R, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18:e330\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(17)30345-5.","journal-title":"Lancet Oncol"},{"key":"4546_CR69","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/neuonc\/noac216","volume":"25","author":"JAF Koekkoek","year":"2023","unstructured":"Koekkoek JAF, van der Meer PB, Pace A, Hertler C, Harrison R, Leeper HE, et al. Palliative care and end-of-life care in adults with malignant brain tumors. Neuro Oncol. 2023;25:447\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noac216.","journal-title":"Neuro Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04546-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:02:08Z","timestamp":1788544928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04546-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":69,"alternative-id":["4546"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04546-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Idoia Morilla has received fees for consulting and speaking services from Novocure, and Roche. Regina Giron\u00e9s has received fees for consulting and attending Congresses from Novocure and Merck. Natalia Luque Caro has received fees for consulting and speaking services from Novocure, Servier and Roche. Sonia del Barco has received fees for consulting from Novocure and attending Congresses from Servier. M. \u00c1ngeles Vaz-Salgado has received fees for consulting and speaking services from Novocure and Servier. Edinson Caviedes, Borja L\u00f3pez de San Vicente Hern\u00e1ndez, and Juana M. Cano, and declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}